Fredrik Alpsten and the Board of Directors of Devyser have now reached an agreement that he will leave his position as CEO of Devyser.

Devyser's Board of Directors has initiated the recruitment of a new CEO. Fredrik Dahl, PhD in Molecular Medicine, currently a board member and well acquainted with the company, has been appointed acting CEO.

The Board of Directors would like to thank Fredrik for his appreciated efforts among both employees, customers and investors. In order to continue developing the company's full potential and increase profitability, the Board of Directors now desires a new leadership.

Devyser - which has seen rapid growth and expanded its international business - remains committed to its strategy going forward.

Fredrik Dahl holds a PhD in Molecular Medicine from Uppsala University and has done research at Stanford University in DNA technology. After his studies at Stanford, Fredrik worked in California at a pioneering research company in DNA sequencing. Thereafter he moved back to Sweden and co-founded Halo Genomics, which was sold to the American Agilent Technologies, and co-founded Vanadis Diagnostics, which was sold to the American diagnostics company PerkinElmer (now Revvity). Fredrik Dahl thus has extensive international experience in various management roles from global research and diagnostics companies.

Fredrik Dahl will remain as a member of Devyser's Board of Directors.